SOCS2, suppressor of cytokine signaling-2, is highly upregulated and has tumor-promoting functions in the advanced stage of chronic myeloid leukemia (56) and in high-grade anal intraepithelial lesions (57). This evidence concerns the gene SOCS2 and chronic myelogenous leukemia, BCR-ABL1 positive.